PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029

Rhea-AI Filing Summary

Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.

PAVmed Inc. director Timothy E. Baxter received a grant of 13,930 shares of restricted common stock as equity compensation. These shares vest on May 20, 2029 and may be forfeited if he does not complete the required service period. Following this award, he directly holds 21,097 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Baxter Timothy E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common stock	13,930	$0.00	--

Holdings After Transaction: Common stock — 21,097 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 13,930 shares Holdings after transaction: 21,097 shares Vesting date: May 20, 2029

3 metrics

Restricted stock grant 13,930 shares Award of PAVmed common stock to director Baxter

Holdings after transaction 21,097 shares Director Baxter’s direct common stock position post-grant

Vesting date May 20, 2029 Single vesting date for the restricted stock award

Key Terms

restricted stock, Long-Term Incentive Equity Plan, vesting, forfeiture

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Long-Term Incentive Equity Plan financial

"under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date"

vesting financial

"with a single vesting date of May 20, 2029"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

forfeiture financial

"Such restricted stock is subject to forfeiture if the requisite service period is not completed"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baxter Timothy E

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	04/02/2026		A		13,930(1)	A	$0(1)	21,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PAVmed (PAVM) director Timothy Baxter report?

Timothy E. Baxter reported receiving 13,930 shares of restricted PAVmed common stock as an equity grant. The award was made at no cash cost to him and is structured as compensation under the company’s long-term incentive equity plan.

How many PAVmed (PAVM) shares does Timothy Baxter hold after this grant?

After the restricted stock grant, Timothy Baxter directly holds 21,097 shares of PAVmed common stock. This total reflects his position immediately following the reported award and indicates his ongoing equity stake as a company director.

When do Timothy Baxter’s new PAVmed (PAVM) restricted shares vest?

The 13,930 restricted shares granted to Timothy Baxter are scheduled to vest on May 20, 2029. Vesting occurs only if he satisfies the required service period specified in PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.

Are Timothy Baxter’s new PAVmed (PAVM) restricted shares subject to forfeiture?

Yes. The footnote states the restricted stock is subject to forfeiture if Baxter does not complete the requisite service period. This means failure to meet the service conditions could cause some or all of the 13,930 shares to be lost.

What plan governs Timothy Baxter’s PAVmed (PAVM) restricted stock grant?

The grant was made under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. This plan provides equity-based compensation, such as restricted stock, to align directors’ and employees’ interests with shareholder value over time.

Was Timothy Baxter’s PAVmed (PAVM) transaction a market purchase or sale?

No. The filing classifies the transaction as a grant or award acquisition, not an open-market trade. Baxter received 13,930 restricted shares at a stated price of $0.0000 per share as part of his compensation, with no reported market buy or sell.